Literature DB >> 1646182

Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity.

H Pijl1, H P Koppeschaar, F L Willekens, I Op de Kamp, H D Veldhuis, A E Meinders.   

Abstract

The effect of fluoxetine on body weight and spontaneous food choice was studied in twenty-three healthy, non-depressed, obese females on an outpatient basis. After a one week placebo run-in period, subjects were randomized to receive either fluoxetine (FXT) 60 mg daily (n = 11) or placebo (P) (n = 12) for 6 weeks in a double blind study design. BMI (35.2 +/- 0.8 vs 36.4 +/- 1.3 kg/m2, mean +/- s.e.m.) and age (38.1 +/- 239 vs 37.3 +/- 2.7 years) were not different in either group. No specific diet was prescribed. On four separate days per 14 days food records were collected. Data were analysed with the use of food composition tables. Statistical analysis was performed using Student's t test for independent samples for data on body weight and calorie intake. Macro-nutrient composition of the diet was analysed using multivariate analysis of variance and post hoc Student's t test for independent samples. All subjects lost weight during fluoxetine treatment. Mean (+/- s.e.m.) weight loss in the fluoxetine treated group was 3.6 +/- 0.5 kg, compared to a mean weight gain of 0.3 +/- 0.5 kg in the placebo treated group (P less than 0.001). In all patients food intake was reduced during fluoxetine treatment and this reduction could fully account for the observed weight loss. The mean total caloric intake per day was significantly lower during fluoxetine treatment compared with placebo (FXT 1123 +/- 118 kcal vs P 1845 +/- 87 kcal, P less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1646182

Source DB:  PubMed          Journal:  Int J Obes


  12 in total

Review 1.  Serotonergic drugs : effects on appetite expression and use for the treatment of obesity.

Authors:  Jason C G Halford; Joanne A Harrold; Emma J Boyland; Clare L Lawton; John E Blundell
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 2.  Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.

Authors:  Karen L Teff; Sangwon F Kim
Journal:  Physiol Behav       Date:  2011-06-12

Review 3.  Serotonergic anti-obesity agents: past experience and future prospects.

Authors:  Jason C G Halford; Emma J Boyland; Clare L Lawton; John E Blundell; Joanne A Harrold
Journal:  Drugs       Date:  2011-12-03       Impact factor: 9.546

Review 4.  Current concepts in the pharmacological management of obesity.

Authors:  P J Carek; L M Dickerson
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

Review 5.  Lorcaserin for the treatment of obesity.

Authors:  L M Redman; E Ravussin
Journal:  Drugs Today (Barc)       Date:  2010-12       Impact factor: 2.245

6.  Acute tryptophan depletion and sweet food consumption by overweight adults.

Authors:  Sherry L Pagoto; Bonnie Spring; Dennis McChargue; Brian Hitsman; Malaina Smith; Bradley Appelhans; Donald Hedeker
Journal:  Eat Behav       Date:  2008-10-30

7.  Serum serotonin levels and bone in rheumatoid arthritis patients.

Authors:  Miguel Bernardes; Tiago Vieira; Raquel Lucas; Jorge Pereira; Lúcia Costa; Francisco Simões-Ventura; Maria João Martins
Journal:  Rheumatol Int       Date:  2017-10-09       Impact factor: 2.631

8.  Metabolic effects of fluoxetine in adults with type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials.

Authors:  Zi Ye; Lili Chen; Zhen Yang; Qin Li; Ying Huang; Min He; Shuo Zhang; Zhaoyun Zhang; Xuanchun Wang; Weiwei Zhao; Ji Hu; Chao Liu; Shen Qu; Renming Hu
Journal:  PLoS One       Date:  2011-07-28       Impact factor: 3.240

9.  Relation of serum serotonin levels to bone density and structural parameters in women.

Authors:  Ulrike I Mödder; Sara J Achenbach; Shreyasee Amin; B Lawrence Riggs; L Joseph Melton; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2010-02       Impact factor: 6.741

Review 10.  Fluoxetine for adults who are overweight or obese.

Authors:  Aurora E Serralde-Zúñiga; Alejandro G Gonzalez Garay; Yanelli Rodríguez-Carmona; Guillermo Melendez
Journal:  Cochrane Database Syst Rev       Date:  2019-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.